Abstracts Archive - Page 2324 of 2425 - ACR Meeting Abstracts

Abstract Number: 1460 • 2012 ACR/ARHP Annual Meeting
Unmasking Latent Pulmonary Arterial Hypertension by Fluid Challenge in Patients with Systemic Sclerosis
Amee Sonigra¹, Melanie Hurford², Patricia Lewis³, David Kilpatrick⁴, Nathan Dwyer⁴ and Jane Zochling³, ¹Medicine, Royal Hobart Hospital, Hobart, Australia, ²Menzies Research Institute, Hobart, Australia, ³Menzies Research Institute Tasmania, Hobart, Australia, ⁴Cardiology, Royal Hobart Hospital, Hobart, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) is associated with high morbidity and mortality in Systemic Sclerosis. Early diagnosis and treatment leads to substantial improvements in quality…
Abstract Number: 1461 • 2012 ACR/ARHP Annual Meeting
Clinical Outcomes of Scleroderma Patients At High Risk for Pulmonary Hypertension. Analysis of the Pulmonary Hyparternsion Assessment and Recognition of Outcomes in Scleroderma Registry
Avram Z. Goldberg¹, Vivien M. Hsu² and Virginia D. Steen³, ¹Div of Rheumatology, North Shore-LIJ Health System, Lake Success, NY, ²Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ³Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is the most frequent cause of death in Systemic Sclerosis (SSc). It is critical to identify patients early to begin…
Abstract Number: 1462 • 2012 ACR/ARHP Annual Meeting
Expert Consensus for Performing Right Heart Catheterization in Suspicion of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis: A Delphi Consensus Study with Cluster Analysis From the Eposs Group
Jerome Avouac¹, Dörte Huscher², Daniel Furst³, Oliver Distler⁴ and Yannick Allanore⁵, ¹Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France
Background/Purpose: Pulmonary hypertension (PH) has emerged as a critical cause of death in systemic sclerosis (SSc). Recent data have highlighted the poorer outcomes of SSc…
Abstract Number: 1463 • 2012 ACR/ARHP Annual Meeting
Pulmonary Hypertension and Interstitial Lung Disease within Pharos: Impact of Extent of Fibrosis and Pulmonary Physiology On Cardiac Hemodynamic Parameters
Aryeh Fischer¹, Stephen C. Mathai², Marcy B. Bolster³, Lorinda Chung⁴, Mary Ellen Csuka⁵, Robyn T. Domsic⁶, Tracy M. Frech⁷, Monique E. Hinchcliff⁸, Vivien M. Hsu⁹, Laura K. Hummers¹⁰, Jason R. Kolfenbach¹¹, Mardi Gomberg-Maitland¹², Aida Manu¹³, Robert W. Simms¹⁴ and Virginia D. Steen¹⁵, ¹Rheumatology / ILD Program, National Jewish Health, Denver, CO, ²Medicine, Johns Hopkins University, Baltimore, MD, ³Medicine, Medical Univ of South Carolina, Charleston, SC, ⁴Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ⁵Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁸Division of Rheumatology, Northwestern Univ Med School, Chicago, IL, ⁹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹²University of Chicago, Chicago, ¹³Rheumatology, Georgetown University Medical Center, Disrict of Columbia, ¹⁴Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of mortality in systemic sclerosis (SSc). Many SSc patients have both…
Abstract Number: 1464 • 2012 ACR/ARHP Annual Meeting
Comparison of Baseline Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis
Heather Gladue¹, Daniel Furst², Veronica Berrocal³, James R. Seibold⁴, Peter A. Merkel⁵, Maureen D. Mayes⁶, Kristine Phillips⁷, Robert W. Simms⁸, Shervin Assassi⁹, Philip J. Clements¹⁰, Paul Maranian¹¹ and Dinesh Khanna¹², ¹University of Michigan, Ann Arbor, MI, ²David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ³Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Scleroderma Research Consultants LLC, Avon, CT, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁸Rheumatology, Boston University School of Medicine, Boston, MA, ⁹Rheumatology, Univ of Texas Health Science Houston, Houston, TX, ¹⁰University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ¹¹Division of Rheumatology, UCLA Medical School, Los Angeles, CA, ¹²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Randomized clinical trials (RCTs) of treatment of diffuse systemic sclerosis (dcSSc) would benefit from a composite index that predicted efficacy better than current standard…
Abstract Number: 1465 • 2012 ACR/ARHP Annual Meeting
World Health Organization Classification of Pulmonary Hypertension and Survival in Systemic Sclerosis Patients in the Pharos Cohort
Jessica K. Gordon¹, Lorinda Chung², Robyn T. Domsic³, Wei-Ti Huang⁴, Stephen L. Lyman⁵, Evelyn M. Horn⁶, Virginia D. Steen⁷ and PHAROS Investigators⁸, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Epidemiology and Statistics, Hospital for Special Surgery, New York, NY, ⁵Research, Hospital for Special Surgery, New York, NY, ⁶Cardiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY, ⁷Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Washington, DC, DC
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH…
Abstract Number: 1466 • 2012 ACR/ARHP Annual Meeting
Patients with Systemic Sclerosis Are Dying of Non-Systemic Sclerosis Related Causes, However Interstitial Lung Disease Remains the Predominant Systemic Sclerosis Related Cause of Death
Rebecca L. Batten and Bridget Griffiths, Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Interstitial Lung Disease Remains the leading Cause of Death in Patients with Systemic Sclerosis, Despite Aggressive Treatment with CyclophosphamideBackground/Purpose: Studies suggest that despite aggressive treatment…
Abstract Number: 1467 • 2012 ACR/ARHP Annual Meeting
Association of Gastroesophageal Factors and Progression of Interstitial Lung Disease in the Canadian Scleroderma Research Group, a Large, Multicenter Database
Xuli Jerry Zhang¹, Ashley Bonner², Murray Baron³, Marie Hudson⁴, Janet E. Pope⁵ and Canadian Scleroderma Research Group⁶, ¹Western University, London, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Montreal, Canada
Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is a leading contributor to mortality in SSc patients. Once lung…
Abstract Number: 1468 • 2012 ACR/ARHP Annual Meeting
Patient Perspective Informs Core Sets, Constructs of Metrics and Communication Tools for Patients with Connective Tissue Disease Related Interstitial Lung Disease
Shikha Mittoo¹, Sid Frankel², Daphne LeSage³, Flavia V. Castelino⁴, Lisa Christopher-Stine⁵, Sonye Danoff⁶, Aryeh Fischer⁷, Laura K. Hummers⁸, Ami A. Shah⁸, Jeffery J. Swigris⁹, Sophia Cenac¹⁰, Sancia Ferguson¹¹, Ignacio Garcia-Valladares¹², Maithy Tran¹³, Harmanjot K. Grewal¹⁴ and Lesley Ann Saketkoo¹⁵, ¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²University of Manitoba, Winnipeg, Canada, ³Center for CCH at State of Louisiana, New Orleans, LA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ⁶Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁷Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Autoimmune Lung Center, National Jewish Health, Denver, CO, ¹⁰Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ¹¹Tulane University School of Medicine, ¹²Rheumatology, Guadalajara, Guadalajara, Mexico, ¹³Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ¹⁵LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA
Background/Purpose: Limited information on the patient experience exists in CTD-ILD. Herein supports that the patients' perspective is essential to informing clinical practice and in…
Abstract Number: 1470 • 2012 ACR/ARHP Annual Meeting
Clinical Features Associated with Anti-Th/to in Non-Scleroderma Patients – Sine Scleroderma?
Ann D. Chauffe¹, Minoru Satoh¹, Angela Ceribelli², Edward K.L. Chan², Yi Li¹, Eric S. Sobel³, Westley H. Reeves⁴ and Michael R. Bubb¹, ¹Medicine, University of Florida, Gainesville, FL, ²Oral Biology, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Autoantibodies in scleroderma (systemic sclerosis, SSc) such as anti-topoisomerase I (Scl-70), RNA polymerase III, centromere, U3RNP/fibrillarin, and Th/To are associated with a unique subset…
Abstract Number: 1471 • 2012 ACR/ARHP Annual Meeting
Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Lorinda Chung¹, Catriona Cramb², William H. Robinson³, Virginia D. Steen⁴ and Roham T. Zamanian⁵, ¹Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ²VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵Stanford University, Palo Alto, CA
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Non-invasive biomarkers are needed to identify…
Abstract Number: 1472 • 2012 ACR/ARHP Annual Meeting
Enhanced Liver Fibrosis Test: A Further Step Toward Depiction of Fibrotic Process in Very Early Diagnosis of Systemic Sclerosis
Francesca Ingegnoli¹, Roberta Gualtierotti², Tommaso Schioppo², Annalisa Orenti³, Patrizia Boracchi³, Chiara Lubatti¹, Sara Lodi Rizzini¹, Antonella Murgo¹, Silvana Zeni⁴, Claudio Mastaglio⁵, Valentina Galbiati⁶, Claudia Grossi⁷, Maria Borghi⁷, William M. Rosenberg⁸ and Pier Luigi Meroni⁹, ¹Dept. of clinical and community science, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ²Dept. of clinical sciences and community health, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ³Dept. of clinical and community science, Medical Statistics and Biometry, University of Milan, Milano, Italy, ⁴Division of Rheumatology, Istituto G. Pini, Milano, Italy, ⁵Moriggia-Pelascini, Gravedona, Italy, ⁶Rheumatology Unit, Ospedale Moriggia-Pelascini, Italia Hospital, Gravedona, Italy, ⁷Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁸Centre for Hepatology - UCL, London, United Kingdom, ⁹Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: Enhanced Liver Fibrosis (ELF) test is derived from an algorithm of 3 serum biomarkers of fibrosis (i.e. tissue inhibitors of matrix metalloproteinases, hyaluronic acid…
Abstract Number: 1473 • 2012 ACR/ARHP Annual Meeting
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Giuseppina Abignano¹, Giovanna Cuomo², Maya H. Buch³, William M. Rosenberg⁴, Gabriele Valentini⁵, Paul Emery⁶ and Francesco Del Galdo⁷, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴Centre for Hepatology - UCL, London, United Kingdom, ⁵Rheumatology/Int Med, Second University of Naples, Rheumatology Unit, Naples, Italy, ⁶Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP),…
Abstract Number: 1474 • 2012 ACR/ARHP Annual Meeting
Interferon-Inducible Chemokines Correlate with Disease Severity in Systemic Sclerosis
Xiaochun Liu¹, Maureen D. Mayes¹, Filemon K. Tan¹, Minghua Wu¹, John D. Reveille², Brock E. Harper³, Hilda T. Draeger⁴, Emilio B. Gonzalez⁵ and Shervin Assassi⁶, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ³Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, ⁴Med/Clinical/Immunology, Univ of TX Health Sci Ctr, San Antonio, TX, ⁵Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁶Rheumatology, Univ of Texas Health Science Houston, Houston, TX
Plasma Interferon Inducible Chemokine Score: Stable Marker of Disease Severity in Systemic SclerosisABSTRACT:Background/Purpose: The most prominent gene expression profile in the peripheral blood of patients…
Abstract Number: 1475 • 2012 ACR/ARHP Annual Meeting
Does Skin Gene Expression Profile Predict Response to Imatinib?
Shervin Assassi¹, Jeffrey T. Chang², Dinesh Khanna³, Xiaochun Liu¹, Daniel Furst⁴ and Maureen D. Mayes⁵, ¹Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ²University of Texas Health Science Center at Houston, Houston, TX, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁵Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Imatinib is a potent inhibitor of TGF-β signaling. Furthermore, a subgroup of SSc patients shows a prominent TGF-β gene expression signature in skin biopsy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].